• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comparison of recombinant and urinary follicle-stimulating hormone preparations in short-term gonadotropin releasing hormone agonist protocol for in vitro fertilization-embryo transfer.重组促卵泡生成素制剂与尿促卵泡生成素制剂在体外受精-胚胎移植短方案促性腺激素释放激素激动剂治疗中的比较
J Assist Reprod Genet. 2001 Apr;18(4):191-6. doi: 10.1023/a:1009408029509.
2
[Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].国产高纯度尿促卵泡素对控制性卵巢刺激中体外受精-胚胎移植结局的影响
Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):838-42.
3
Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.在接受重组促卵泡激素和促性腺激素释放激素（GnRH）拮抗剂联合治疗进行卵巢刺激后的体外受精患者中，给予重组人绒毛膜促性腺激素、重组促黄体生成素或GnRH激动剂诱导最终卵母细胞成熟后，未补充黄体期的特征。
J Clin Endocrinol Metab. 2003 Sep;88(9):4186-92. doi: 10.1210/jc.2002-021953.
4
The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.促性腺激素释放激素激动剂引发的初始 flare-up 可作为 40 - 48 岁正常促性腺激素水平女性当前体外受精 - 胚胎移植治疗周期中卵巢反应的预测指标。
J Assist Reprod Genet. 1996 May;13(5):395-400. doi: 10.1007/BF02066171.
5
Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study.体外受精前使用重组人促卵泡激素与尿促卵泡素（联合长效促性腺激素释放激素类似物方案）进行超排卵：一项比较研究。
J Assist Reprod Genet. 1995 Jan;12(1):26-31. doi: 10.1007/BF02214125.
6
A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.两种卵巢刺激方案与促性腺激素释放激素（GnRH）拮抗剂联合治疗用于体外受精的随机比较，这两种方案分别是在周期第2天或第5天开始使用重组促卵泡激素并与标准长效GnRH激动剂方案进行对比。
J Clin Endocrinol Metab. 2003 Jan;88(1):166-73. doi: 10.1210/jc.2002-020788.
7
Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH.在使用促性腺激素释放激素激动剂（GnRH-a）与重组促卵泡生成素（FSH）以及GnRH-a与尿促卵泡素的体外受精周期中出现的过早黄素化。
Fertil Steril. 1996 Aug;66(2):275-80. doi: 10.1016/s0015-0282(16)58453-2.
8
A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report.来曲唑作为低成本体外受精方案用于卵巢反应不良女性的随机单盲对照试验：初步报告
Hum Reprod. 2004 Sep;19(9):2031-5. doi: 10.1093/humrep/deh359. Epub 2004 Jun 24.
9
Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer.在接受体外受精-胚胎移植的患者中，使用促性腺激素释放激素激动剂进行垂体抑制周期时，基于第3天血清卵泡刺激素浓度预测卵巢储备功能。
Gynecol Endocrinol. 2004 Jun;18(6):335-40. doi: 10.1080/0951359042000196303.
10
A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.一项关于降低剂量（33或25微克）促性腺激素释放激素激动剂长方案用于体外受精-胚胎移植中基础血清促卵泡生成素水平高的患者多卵泡卵巢刺激的初步研究。
Gynecol Endocrinol. 2005 Oct;21(4):227-31. doi: 10.1080/09513590500282125.

引用本文的文献

1
The Type of Follicle-Stimulating Hormone Medication Given for In Vitro Fertilization Impacts Oocyte Retrieval: A Systematic Review and Meta-Analysis.用于体外受精的促卵泡激素药物类型对卵母细胞采集的影响：一项系统评价和荟萃分析。
Clin Pharmacol Ther. 2025 Oct;118(4):790-802. doi: 10.1002/cpt.70014. Epub 2025 Jul 31.
2
Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis.辅助生殖的控制性卵巢刺激方案：一项网状荟萃分析。
Cochrane Database Syst Rev. 2025 Jul 1;7(7):CD012586. doi: 10.1002/14651858.CD012586.pub2.
3
The therapeutic effects of rFSH versus uFSH/uHMG on ovarian stimulation in women undergoing assisted reproductive technology: a meta-analysis of randomized controlled trials.rFSH 与 uFSH/uHMG 对接受辅助生殖技术的女性卵巢刺激的治疗效果：随机对照试验的荟萃分析。
Arch Gynecol Obstet. 2024 Jun;309(6):2529-2555. doi: 10.1007/s00404-023-07095-5. Epub 2023 Jul 20.
4
The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.重组促卵泡激素阿尔法与尿源性人促卵泡激素在辅助生殖技术周期中卵巢刺激的累积活产率。
J Ovarian Res. 2022 Jun 21;15(1):74. doi: 10.1186/s13048-022-01009-w.
5
Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis.实现活产所需的重组促卵泡素、高纯度人绝经期促性腺激素和高纯度促卵泡素用量：一项系统评价和荟萃分析。
Hum Reprod Open. 2019 Jun 1;2019(3):hoz008. doi: 10.1093/hropen/hoz008. eCollection 2019.
6
Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles.重组促性腺激素与尿促性腺激素用于辅助生殖技术周期中的卵巢刺激。
Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD005354. doi: 10.1002/14651858.CD005354.pub2.
7
Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis.重组促卵泡生成素与高纯度尿促卵泡生成素在诱导排卵中的应用比较（重组促卵泡生成素与高纯度尿促卵泡生成素对比研究）：一项前瞻性随机研究及成本最小化分析
Reprod Biol Endocrinol. 2006 Jul 18;4:38. doi: 10.1186/1477-7827-4-38.

本文引用的文献

1
Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta.重组促卵泡激素在体外受精治疗中的应用——促卵泡素α和促卵泡素β的临床经验
Hum Reprod. 2000 Feb;15(2):239-44. doi: 10.1093/humrep/15.2.239.
2
A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer.两种重组人促卵泡激素制剂在接受体外受精-胚胎移植患者中的疗效和耐受性比较。
Fertil Steril. 2000 Jan;73(1):114-6. doi: 10.1016/s0015-0282(99)00450-1.
3
Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.两种重组促卵泡激素制剂在体外受精中的比较：一项随机临床研究。
Hum Reprod. 1999 Nov;14(11):2709-15. doi: 10.1093/humrep/14.11.2709.
4
A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
Hum Reprod. 1999 Oct;14(10):2442-7. doi: 10.1093/humrep/14.10.2442.
5
Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction.重组促卵泡生成素与尿促卵泡素在辅助生殖中用于卵巢刺激的比较。
Hum Reprod. 1999 Sep;14(9):2207-15. doi: 10.1093/humrep/14.9.2207.
6
Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome.在促卵泡激素和雌二醇基础浓度正常的低反应者中使用重组促卵泡刺激素刺激：改善生殖结局。
Hum Reprod. 1999 Jun;14(6):1431-4. doi: 10.1093/humrep/14.6.1431.
7
Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Recombinant Human FSH Product Development Group.重组促卵泡激素：首个用于治疗不孕症的生物技术产品的研发。重组人促卵泡激素产品研发小组。
Hum Reprod Update. 1998 Nov-Dec;4(6):862-81. doi: 10.1093/humupd/4.6.862.
8
A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women.一项针对无排卵性不孕女性，比较重组人促卵泡激素慢性低剂量与传统促排卵方案的前瞻性研究。
Hum Reprod. 1998 Oct;13(1O):2688-92. doi: 10.1093/humrep/13.10.2688.
9
Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.重组人促黄体生成素支持重组人促卵泡激素诱导的促黄体生成素和促卵泡激素缺乏的无排卵女性卵泡发育：一项剂量探索性研究。欧洲重组人促黄体生成素研究组。
J Clin Endocrinol Metab. 1998 May;83(5):1507-14. doi: 10.1210/jcem.83.5.4770.
10
Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.重组促卵泡生成素（FSH；果纳芬）在枸橼酸氯米芬抵抗、正常促性腺激素性慢性无排卵女性中比尿促卵泡素（美诺孕）更有效：一项前瞻性、多中心、评估者盲法、随机临床试验。欧洲果纳芬协作性无排卵研究组。
Fertil Steril. 1998 Jan;69(1):19-25. doi: 10.1016/s0015-0282(97)00423-8.

重组促卵泡生成素制剂与尿促卵泡生成素制剂在体外受精-胚胎移植短方案促性腺激素释放激素激动剂治疗中的比较

Comparison of recombinant and urinary follicle-stimulating hormone preparations in short-term gonadotropin releasing hormone agonist protocol for in vitro fertilization-embryo transfer.

作者信息

Hugues J N, Bry-Gauillard H, Bständig B, Uzan M, Cedrin-Durnerin I

机构信息

Reproductive Medecine Unit, Department of Gynaecology and Obstetrics, University Paris XIII, France.

出版信息

J Assist Reprod Genet. 2001 Apr;18(4):191-6. doi: 10.1023/a:1009408029509.

DOI:10.1023/a:1009408029509
PMID:11432109
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3455363/
Abstract

PURPOSE

To compare the efficiency and efficacy of two recombinant human FSH (r-FSH) and urinary (u-FSH) preparations in patients undergoing superovulation for IVF-ET using a short-term gonadotropin releasing hormone agonist (GnRH-a) (Triptorelin) protocol.

METHODS

A total of 88 women undergoing IVF-ET were included in this prospective study. They were randomized to receive u-FSH (150 IU/d), follitropin-alpha (100 IU/d), or follitropin-beta (100 IU/d) for 2 days, and dosages were subsequently adjusted according to the ovarian response.

RESULTS

The FSH dose required for the overall stimulation was significantly lower in patients treated with r-FSH than in those treated with u-FSH while serum FSH values were higher in the latter group. There were no statistically significant differences in ovarian response and IVF outcome between r-FSH preparations.

CONCLUSIONS

Recombinant FSH preparations have a higher efficiency than urinary ones in patients undergoing IVF-ET using a short-term GnRH-a protocol. In this situation, the two recombinant follitropins have comparable effectiveness.

摘要

目的

采用短期促性腺激素释放激素激动剂（GnRH-a）（曲普瑞林）方案，比较两种重组人促卵泡激素（r-FSH）制剂与尿源性促卵泡激素（u-FSH）制剂在接受体外受精-胚胎移植（IVF-ET）超排卵患者中的有效性和功效。

方法

本前瞻性研究共纳入88例接受IVF-ET的女性。她们被随机分为接受u-FSH（150IU/天）、重组促卵泡素α（100IU/天）或重组促卵泡素β（100IU/天）治疗2天，随后根据卵巢反应调整剂量。

结果

r-FSH治疗组患者总体刺激所需的FSH剂量显著低于u-FSH治疗组，而后者血清FSH值更高。r-FSH制剂之间在卵巢反应和IVF结局方面无统计学显著差异。

结论

在采用短期GnRH-a方案进行IVF-ET的患者中，重组FSH制剂比尿源性制剂具有更高的效率。在这种情况下，两种重组促卵泡素具有相当的有效性。